ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

Clinical Cancer Research 2026

View at publisher
Authors: Félix Blanc-Durand, Catherine Genestie, S. Nikolaev, Raphaël Leman, David N. Church, Guillaume Beinse, Olivier Tredan, Leïla Bengrine Lefevre, Pierre-Emmanuel Brachet, Coriolan Lebreton, Guillaume Meynard, P. Fournel
+18 more Jean‐Sébastien Frenel, Frédèric Selle, Corina Cornila, Yolanda Fernandez Diez, Elise Bonnet, Antoine Arnaud, Emilie Kaczmarek, Philippe Follana, Anne‐Claire Hardy‐Bessard, Michel Fabbro, Isabelle Cojean Zelek, Sophie Roche, Delphine Duliege, Marie‐Ange Mouret‐Reynier, Patrick Bouchaert, Jerome Alexandre, Florence Joly, Alexandra Leary
DOI: 10.1158/1078-0432.ccr-25-2758
Cited by: 0
References: 34

Abstract

PURPOSE: Aromatase inhibitors (AI) are used to treat estrogen receptor (ER)-positive low-grade endometrioid endometrial cancer. In breast cancer, ESR1 mutations are rare at diagnosis (

Fields of Study & Subjects

Estrogen and related hormone effects Breast Cancer Treatment Studies Advanced Breast Cancer Therapies

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
5
Pages
963–969
Publication date
8 January 2026
Language
EN